First Investment: 2014
EXIT - NYSE: DNA
The solutions to many of the hardest problems in agriculture, nutrition, pharmaceuticals, energy production, and chemical and material processing lie in synthetic biology. Ginkgo runs biological foundries where automation, machine learning, and analytics work in synchrony to help partners scale up the engineering and manufacture of novel enzymes, proteins, small molecules, and microbial strains.
News & Insights
Thoughts
Explore Companies
Newleos Therapeutics
Transforming the treatment of anxiety and other neuropsychiatric disorders
Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs